

产品名称: **TP-0903**
 产品别名: **Dubermatinib**

生物活性:

Description	Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.				
IC ₅₀ & Target	IC50: 27nM (Axl)[1]				
In Vitro	Dubermatinib (TP-0903) displays a potent activity against AXL with an IC50 of 0.027 μM. Dubermatinib (TP-0903) shows extremely potent activity in cell viability assays with an IC50 of 6 nM against the pancreatic cancer cell line PSN-1. Dubermatinib (TP-0903) is evaluated for its ability to block GAS6-mediated activation of AXL in pancreatic cancer cells. PSN-1 cells are serum-starved and then stimulated with GAS6 in the presence of various concentrations of TP-0903[1].				
Solvent&Solubility	<i>In Vitro:</i> DMSO : ≥ 30 mg/mL (58.13 mM) * "≥" means soluble, but saturation unknown.				
		<div><div>Solvent</div><div>Mass</div><div>Concentration</div></div>	1 mg	5 mg	10 mg
	Preparing	1 mM	1.9378 mL	9.6888 mL	19.3776 mL
	Stock Solutions	5 mM	0.3876 mL	1.9378 mL	3.8755 mL
		10 mM	0.1938 mL	0.9689 mL	1.9378 mL
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80℃，6 months；-20℃，1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。					
References	[1]. Mollard A, et al. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.				

实验参考:

Cell Assay	For cell proliferation assays, 45 μL containing 1000 cells per well are seeded into solid white 384-well plates in appropriate media. The following day, Dubermatinib (TP-0903) is diluted in serum free growth media to 10x desired concentrations and 5 μL is added to each well. Combined compound and cells are incubated for 96 hours. Following incubation, 40 μL of ATP-Lite solution is added to each well, incubated for an additional 10 minutes at room temperature and luminescence is measured on an microplate reader[1].
References	[1]. Mollard A, et al. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.